RE:RE:RE:The breadcrumbs I see in the IR
I believe Spectral is being extremely selective in treating patients with PMX in order to assure an outcome that is positive. I believe the faster enrollment rate for the Euphrates trial was easier and quicker because the focus was more on treating patients closer to 9 using the EEA diagnostic tool. Those patients had nothing to lose since they were at death's door. For most patients at 9 or 9 plus they had nothing to lose and everything to gain by getting the PMX treatment.
Hopefully, the cautious selectivity of patient participants in the current test will lead to a better end result which will lead to a greater value for PMX, Spectral, etc.